• There has been a growing interest in expanding the applications of palladium complexes in anti-cancer.
• The main challenge for the development of anticancer palladium(II) complexes is their high reactivities toward sulfur-containing biomolecules, such as glutathione (GSH), and ease of substitution reactions under physiological conditions, leading to low in vivo stability and multiple speciation that complicates the potential therapeutic applications.

• High stability in vitro and in the presence of physiological thiols
• Potent cytotoxicity against cancer cells
• Effective in vivo anticancer activities 
• Involve induction of mitochondrial dysfunction and inhibition of EGFR signalling pathways

• Platform technology for developing Palladium (II) N-heterocyclic carbene (NHC) complexes
• Anti-cancer drug

Patents

• PCT Application No. PCT/CN2016/093965

IP Status

• Patent application submitted